Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0MHAHZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Coltuximab ravtansine
|
|||||
| Synonyms |
Anti-CD19 humanized monoclonal antibody conjugated to DM4; Anti-CD19-DM4 immunoconjugate; Coltuximab ravtansine; HUB4-DM4, SAR34 19; HuB4-DM4; Maytansin-loaded anti-CD19 mAb; SAR-3419; SAR3419
Click to Show/Hide
|
|||||
| Organization |
ImmunoGen, Inc.; Sanofi
|
|||||
| Drug Status |
Phase 2 (Terminated)
|
|||||
| Indication |
In total 3 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
3 to 4
|
|||||
| Structure |
|
|||||
| Antibody Name |
Coltuximab
|
Antibody Info | ||||
| Antigen Name |
B-lymphocyte antigen CD19 (CD19)
|
Antigen Info | ||||
| Payload Name |
Mertansine DM4
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
N-succinimidyl 4-(2-pyridyldithio) butanoate (SPDB)
|
Linker Info | ||||
| Conjugate Type |
Random Cysteines
|
|||||
| Combination Type |
ravtansine
|
|||||
| Puchem SID | ||||||
| Drugbank ID | ||||||
| DrugMap ID | ||||||
| TTD ID | ||||||
| ChEBI ID | ||||||
